74% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target PD-1 · moa checkpoint-inhibition+chemoradiation · failure mode none
- premise Small cell lung cancer is genomically unstable with high tumor mutational burden, and PD-1/PD-L1 blockade added to platinum-etoposide extended survival in extensive-stage disease (e.g. serplulimab in ASTRUM-005), establishing checkpoint sensitivity of SCLC
- premise In limited-stage SCLC specifically, consolidation durvalumab after concurrent chemoradiation improved both PFS and OS versus placebo in the ADRIATIC phase 3, directly de-risking the question of whether a checkpoint inhibitor adds to chemoradiation in this stage
- inference This trial applies the same PD-1-plus-chemoradiation strategy with serplulimab in limited-stage SCLC, so the positive ADRIATIC readout makes a PFS benefit the expected, precedent-backed outcome rather than a novel bet
- prediction PFS is met in the intended direction with HR below 0.8